Yazar "Tuncel, Ferah" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Clinicopathological features of breast cancer cases and their relationship with immunohistochemical findings
    (2020) Tuncel, Ferah; Gokalp Satici, Fadime Eda; Duman, Aslihan Alpaslan; Bozkurt, Funda; Dag, Ahmet
    Aim: To determine the relationship between established prognostic markers and Ki67 proliferative index in breast cancer patients and investigate variations of prognostic parameters between material types (tru-cut biopsy or resection). Material and Methods: Breast cancer cases reported in our laboratory between July 2015 and December 2019, as well as estrogen receptor (ER), progesterone receptor (PR), CerbB2, Ki-67 staining results, tumor type, histologic grade, tumor size, lymph node metastasis status parameters were obtained from the automation system. Tru-cut biopsy and resection materials were evaluated and the parameters were compared. Results: 726 materials taken from 571 adult patients were included in this study. 297 (40.9%) of the cases were evaluated by tru-cut biopsy and 430 (59.1%) were resection material. The mean ER staining percentage was 86.5 (± 10.36) and it was 61.65 (± 22.84) for PR. Ki-67 proliferative index had an average value of 26.58 (± 17.67). There was no difference between the material types in terms of immunohistochemical markers, whereas there were differences between the two material types in histological grade results.Conclusion: Besides established immunohistochemical prognostic markers, Ki67 proliferative index should be utilized in breast cancer cases and determination of histological grade in tru-cut biopsies is valuable for the clinical management of the tumor.
  • Küçük Resim
    Öğe
    Novel immunohistochemical marker in the differential diagnosis of sex cord-stromal tumors: SF-1
    (2022) Alpaslan Duman, Aslihan; Ates Ozdemir, Deniz; Tuncel, Ferah; Usubutun, Alp; Usubutun, Alp
    Aim: Sex cord-stromal tumors are relatively uncommon tumors which constitute approximately 8% of all primary ovarian neoplasms. Morphologic differentiation of non-SCST from SCSTs can be challenging due to microscopic overlap. Immunohistochemistry is beneficial in challenging cases. Inhibin and calretinin have limited sensitivity and specificity, a more sensitive marker is required. SF-1 is known as a promising immunohistochemical marker in the differentiation of SCST from non-SCST ovarian tumors. For this purpose, various non-SCSTs (metastatic and non-metastatic) having morphologic overlap with SCSTs, and multiple SCSTs were stained with SF-1 antibody to elucidate its importance in morphologically challenging cases. Materials and Methods: Twenty-three SCST, 40 non-SCSTs, and an ectopic adrenal tissue were stained with SF-1, and also the percentage and the intensity were scored. SF-1 immunoreactivity was seen in all 23 SCST with varying degrees of intensity and percentage. In contrast, non-SCSTs were negative in all regarding to SF-1. Ectopic adrenal gland tissue and ovarian stroma are positive as non-tumoral lesions. Results: In our series, SF-1 immunoreactivity was seen in all 23 SCST and ectopic adrenal tissue with varying degrees of intensity and diffuseness. In contrast, non-SCSTs were all negative concerning SF-1. In addition; we observed nuclear positivity with SF-1 in 15-75% of the sclerosing stromal tumor cells, whereas inhibin and calretinin were negative in all 4 cases. Conclusion: Our data shows that SF-1 is a nuclear, reliable and surrogate marker for all SCSTs, and can be used routinely.